Immunogenicity and Safety of Pentavalent Meningococcal MenABCWY Vaccine in Adolescents and Young Adults: Integrated Evidence from Late-Phase Clinical Trials
Posted inClinical Updates news Pediatrics Public Health

Immunogenicity and Safety of Pentavalent Meningococcal MenABCWY Vaccine in Adolescents and Young Adults: Integrated Evidence from Late-Phase Clinical Trials

This review synthesizes phase 2 and 3 trial data demonstrating that the pentavalent MenABCWY vaccine is immunologically non-inferior and well tolerated compared with MenB-fHbp and MenACWY-CRM vaccines, offering a simplified, effective vaccination strategy against invasive meningococcal disease in adolescents and young adults.